Alumis stock slides after envudeucitinib misses lupus trial goal
Alumis shares were pacing for a worst day on record after the company said its lupus drug candidate, envudeucitinib, failed to meet the main goal in a mid-stage trial.
Alumis shares were pacing toward their worst day on record Tuesday after the biotech said its lupus drug candidate, envudeucitinib, failed to meet the main goal of a mid-stage trial. Researchers were evaluating the oral treatment's efficacy in patients with moderate-to-severe systemic lupus erythematosus.